Target Name: SNORD115-12
NCBI ID: G100033449
Review Report on SNORD115-12 Target / Biomarker Content of Review Report on SNORD115-12 Target / Biomarker
Other Name(s): small nucleolar RNA, C/D box 115-12 | Small nucleolar RNA, C/D box 115-12 | HBII-52-12

Exploring SNORD115-12: Unveiling its Significance as a Potential Disease Drug Target or Biomarker

Understanding SNORD115-12

In the vast world of molecular biology, the discovery of small nucleolar RNAs (snoRNAs) has opened up new avenues of research and potential therapeutic targets. One such snoRNA, SNORD115-12, has recently gained attention for its potential role as a disease drug target or biomarker. In this article, we delve into the intricacies of SNORD115-12, exploring its functions, significance, and the implications it holds for future medical advancements.

The Role of snoRNAs

SnoRNAs are a unique class of non-coding RNAs that primarily reside in the nucleolus, a subnuclear compartment responsible for ribosome biogenesis. Traditionally, snoRNAs were believed to be solely involved in modification of ribosomal RNAs (rRNAs), essential for proper ribosome function. However, recent studies have shed light on additional roles of snoRNAs, expanding their known functions.

The Enigma of SNORD115-12

SNORD115-12 is a snoRNA located on chromosome 15q11-13, a region known for its involvement in various neurodevelopmental disorders, including Prader-Willi syndrome and Angelman syndrome. Initially discovered in 2001, SNORD115-12 has since been a subject of scientific fascination due to its peculiar characteristics and potential implications.

It is intriguing to note that SNORD115-12 is highly expressed exclusively in the brain, specifically in the neurons of the hippocampus and cerebellum. This brain-region specificity suggests that the snoRNA is intricately involved in the regulation of neurological processes and potentially plays a crucial role in maintaining brain homeostasis.

Potential as a Disease Drug Target

The brain-specific expression pattern of SNORD115-12 has piqued the interest of researchers as it may serve as a valuable target for drug development in various neurological disorders. By understanding the snoRNA's precise mechanisms and its involvement in disease pathogenesis, scientists can decipher potential therapeutic interventions that manipulate SNORD115-12 expression or activity.

Studies exploring the role of snoRNAs in neurodevelopmental disorders have hinted at the possible involvement of SNORD115-12 dysregulation in diseases such as epilepsy and autism spectrum disorders. Identifying the exact mechanisms by which SNORD115-12 influences disease progression could lead to the development of targeted therapies to alleviate symptoms or slow down disease progression.

Additionally, recent advancements in gene-editing technologies, such as CRISPR-Cas9, offer promising avenues for manipulating snoRNA expression. By utilizing these techniques, researchers can potentially modulate SNORD115-12 expression levels, allowing for precise intervention in disease pathways.

Insights from Biomarker Research

Biomarkers play a crucial role in disease diagnosis, prognosis, and therapeutic monitoring. They provide objective measures that aid in disease classification and treatment planning. For this reason, SNORD115-12's potential as a biomarker is an area of active investigation.

Preliminary studies have shown altered expression levels of SNORD115-12 in specific neurological disorders, indicating its potential as a diagnostic biomarker for conditions affecting the hippocampus and cerebellum. By quantifying the expression levels of this snoRNA through non-invasive techniques, such as blood or cerebrospinal fluid analysis, clinicians may be able to identify early-stage neurological disorders, improving patient outcomes through early intervention.

However, further research is necessary to validate SNORD115-12 as a reliable biomarker for neurological disorders. Large-scale studies involving diverse patient populations and comprehensive molecular profiling are crucial for establishing its diagnostic value and assessing its sensitivity and specificity.

Future Prospects

As the field of RNA biology continues to evolve, unraveling the secrets of snoRNAs like SNORD115-12 holds immense potential for future medical advancements. Exploring its roles as a drug target and biomarker opens up possibilities for tailored therapies and personalized medicine.

Further deciphering the precise mechanisms by which SNORD115-12 influences neurological processes will enable scientists to develop innovative treatments for neurodevelopmental disorders. Additionally, optimizing techniques for SNORD115-12 detection and quantification will pave the way for its incorporation into routine clinical practice, providing clinicians with valuable insights into disease progression and treatment response.


SNORD115-12, an enigmatic snoRNA primarily expressed in the brain, has garnered attention as a potential disease drug target and biomarker. Its brain-region specificity and involvement in neurodevelopmental disorders make it an intriguing focus for further research. By unraveling its mechanisms of action and validating its diagnostic value, the applications of SNORD115-12 in personalized medicine are within reach. As scientists delve deeper into the mysteries surrounding SNORD115-12, we await advancements that may revolutionize the diagnosis and treatment of neurological disorders.

Protein Name: Small Nucleolar RNA, C/D Box 115-12

The "SNORD115-12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD115-12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNORD115-13 | SNORD115-14 | SNORD115-15 | SNORD115-16 | SNORD115-17 | SNORD115-18 | SNORD115-19 | SNORD115-2 | SNORD115-20 | SNORD115-21 | SNORD115-22 | SNORD115-24 | SNORD115-25 | SNORD115-27 | SNORD115-28 | SNORD115-29 | SNORD115-3 | SNORD115-30 | SNORD115-31 | SNORD115-32 | SNORD115-33 | SNORD115-36 | SNORD115-37 | SNORD115-38 | SNORD115-39 | SNORD115-4 | SNORD115-40 | SNORD115-41 | SNORD115-42 | SNORD115-43 | SNORD115-44 | SNORD115-48 | SNORD115-5 | SNORD115-6 | SNORD115-7 | SNORD115-8 | SNORD115-9 | SNORD116-1 | SNORD116-10 | SNORD116-11 | SNORD116-12 | SNORD116-13 | SNORD116-14 | SNORD116-15 | SNORD116-16 | SNORD116-17 | SNORD116-18 | SNORD116-19 | SNORD116-2 | SNORD116-20 | SNORD116-21 | SNORD116-22 | SNORD116-23 | SNORD116-24 | SNORD116-25 | SNORD116-26 | SNORD116-27 | SNORD116-28 | SNORD116-29 | SNORD116-3 | SNORD116-4 | SNORD116-5 | SNORD116-6 | SNORD116-7 | SNORD116-8 | SNORD116-9 | SNORD116@ | SNORD117 | SNORD118 | SNORD119 | SNORD11B | SNORD12 | SNORD121A | SNORD121B | SNORD123 | SNORD124 | SNORD125 | SNORD126 | SNORD12B | SNORD12C | SNORD13 | SNORD139 | SNORD13P2 | SNORD13P3 | SNORD14A | SNORD14B | SNORD14C | SNORD14D | SNORD14E | SNORD15A | SNORD15B | SNORD16 | SNORD17 | SNORD18A | SNORD18C | SNORD19 | SNORD19B | SNORD1A | SNORD1B | SNORD1C